Invenfin, 4Di Capital, Allectus Capital, Mogul Capital, Tenhong Holdings, Analog Devices, Hannover Re, Convergence Partners, Stellar Capital Partners, Nedbank Corporate and Investment Bank, Delos, OneBio, Virgin Group, Lireas, Allen & Co, Acequia Capital, Rachel Diamond, Halls Investments, Bremer Investments, Errol Damelin, Dietco’s investment into LifeQ’s operations in global regions for USD 47 million

Lead party: OneBio Venture Studio (lead investor/buyer)Coverage: Meridian Capital (investment and transaction tracker; data from Partner Researchers, editorially reviewed). Target: LifeQ, Inc (private company) · Sector: Healthcare, Biotechnology · Countries of operation: South Africa Transaction type: Investment · Asset class: Venture Capital · Strategy: Venture Equity · Instrument: Equity · Round: Series A · Deal…


Lead party: OneBio Venture Studio (lead investor/buyer)

Coverage: Meridian Capital (investment and transaction tracker; data from Partner Researchers, editorially reviewed).

Target: LifeQ, Inc (private company) · Sector: Healthcare, Biotechnology · Countries of operation: South Africa

Transaction type: Investment · Asset class: Venture Capital · Strategy: Venture Equity · Instrument: Equity · Round: Series A · Deal amount: US$47m · Fund: 4Di Capital Fund II

Lead investor/buyer: OneBio Venture Studio · Investors/buyers: Invenfin Proprietary Limited, 4D Innovative Capital (Pty) Ltd, Allectus Capital, Mogul Capital, Tenhong Holdings, Analog Devices, Hannover Re, Convergence Partners Management (Pty) Ltd, Delos, Virgin Group, Lireas Holdings (Pty) Ltd., Allen & co, Acequia Capital, Rachel Diamond, Halls Investments, Bremer Investments, Errol Damelin, Dietco, OneBio Venture Studio, Stellar Capital Partners Limited, Nedbank Group Limited

Legal advisers: not identified in the source record.

Source: announced 26 May 2021. Original announcement: biospace.com.